Bristol Myers Squibb BMY suffered a setback in the late-stage ODYSSEY-HCM study evaluating cardiovascular drug Camzyos (mavacamten). The phase III study was evaluating Camzyos for the treatment of ...
CHONGQING, CHINA - APRIL 20: In this photo illustration, the Bristol Myers Squibb logo is displayed on a smartphone screen, with the company's signature purple branding in the background, on April 20, ...
April 14 (Reuters) - (This April 14 story has been corrected to change the headquarters to 'New Jersey' from 'New York' in paragraph 2, and to remove extraneous words in paragraph 3) Bristol Myers ...
Shares of Bristol Myers Squibb BMY gained 5.62% after the company announced the continuation of the phase III ADEPT-2 study on Cobenfy in psychosis associated with Alzheimer's disease. The news ...
Bristol Myers Squibb is undervalued despite the looming patent cliff, as its robust pipeline and strong cash flow position it for future growth. The impact of Eliquis' patent expiry is overstated, ...
Bristol Myers BMY announced that it will discontinue the late-stage Librexia study evaluating the efficacy and safety of pipeline candidate milvexian when added to the standard of care (conventional ...
Bristol Myers Squibb BMY announced positive data from the late-stage study on iberdomide in patients with relapsed or refractory multiple myeloma (RRMM). The phase III EXCALIBER-RRMM (NCT04975997) is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback